Insmed (FRA:IM8N) Construction In Progress : €48.8 Mil (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Insmed Construction In Progress?

Insmed's quarterly construction in progress increased from Jun. 2024 (€40.5 Mil) to Sep. 2024 (€42.2 Mil) and increased from Sep. 2024 (€42.2 Mil) to Dec. 2024 (€48.8 Mil).

Insmed's annual construction in progress increased from Dec. 2022 (€27.9 Mil) to Dec. 2023 (€32.5 Mil) and increased from Dec. 2023 (€32.5 Mil) to Dec. 2024 (€48.8 Mil).

Insmed Construction In Progress Historical Data

The historical data trend for Insmed's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Construction In Progress Chart

Insmed Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Construction In Progress

Get a 7-Day Free Trial

17.94

24.59

27.88

32.51

48.83

Insmed Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Construction In Progress	Get a 7-Day Free Trial															32.51	36.10	40.52	42.22	48.83

Insmed Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Insmed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (FRA:IM8N) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

INSM:USA 0JAV:UK

Address

700 US Highway 202/206, Bridgewater, NJ, USA, 08807

Website

https://www.insmed.com

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Insmed Headlines

No Headlines